Next Generation Sequencing (NGS) Target Approach for Undiagnosed Dysglycaemia
by
, , , , , and
Concetta Aloi
1,†,
Alessandro Salina
1,*,†,
Francesco Caroli
2,
Renata Bocciardi
2,3,
Barbara Tappino
1,
Marta Bassi
3,4,
Nicola Minuto
4,
Giuseppe d’Annunzio
4 and
Mohamad Maghnie
3,4 1
LABSIEM (Laboratory for the Study of Inborn Errors of Metabolism), IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
2
UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
3
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, 16100 Genoa, Italy
4
Department of Pediatrics, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Life 2023, 13(5), 1080; https://doi.org/10.3390/life13051080
Submission received: 30 March 2023
/
Revised: 18 April 2023
/
Accepted: 21 April 2023
/
Published: 24 April 2023
(This article belongs to the Section Genetics and Genomics)
Abstract
:Next-generation sequencing (NGS) has revolutionized the field of genomics and created new opportunities for basic research. We described the strategy for the NGS validation of the “dysglycaemia panel” composed by 44 genes related to glucose metabolism disorders (MODY, Wolfram syndrome) and familial renal glycosuria using Ion AmpliSeq technology combined with Ion-PGM. Anonymized DNA of 32 previously genotyped cases with 33 different variants were used to optimize the methodology. Standard protocol was used to generate the primer design, library, template preparation, and sequencing. Ion Reporter tool was used for data analysis. In all the runs, the mean coverage was over 200×. Twenty-nine out of thirty three variants (96.5%) were detected; four frameshift variants were missed. All point mutations were detected with high sensitivity. We identified three further variants of unknown significance in addition to pathogenic mutations previously identified by Sanger sequencing. The NGS panel allowed us to identify pathogenic variants in multiple genes in a short time. This could help to identify several defects in children and young adults that have to receive the genetic diagnosis necessary for optimal treatment. In order not to lose any pathogenic variants, Sanger sequencing is included in our analytical protocol to avoid missing frameshift variants.
1. Introduction
Dysglycaemia refers to an abnormality in blood glucose level, which can include hypoglycaemia (low blood glucose level) or hyperglycaemia (high blood glucose level). Monogenic diabetes is a rare form of inherited diabetes mellitus caused by heterozygous or homozygous defects in a single gene involved in β-cell development or function. It accounts for approximately 1% to 6% of pediatric diabetes patients [1]. In fact, until now, most cases of monogenic diabetes remain undiagnosed [2]. The most common type of monogenic diabetes is MODY (maturity-onset diabetes of the young, MIM # 606391) and, to date, 14 subtypes are known [3] representing 2–5% of diabetes cases in Europe [4,5,6,7]. Permanent neonatal diabetes mellitus (PNDM, MIM #606176) is another form of monogenic diabetes characterized by persistent hyperglycemia within the first 12 months of life in general, requiring continuous treatment. Affected patients often respond well to sulfonylureas, and insulin may not be necessary. Wolfram syndrome (WS, MIM #222300), a rare autosomal recessive neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, is caused by bi-allelic defects in WFS1 gene. Patients with familial renal glycosuria (FRG, MIM #233100) have decreased renal tubular reabsorption of glucose from urine in the absence of hyperglycemia and any other signs of tubular dysfunction. It is caused by SLC5a2 mono or bi-allelic mutations. Congenital hyperinsulinism (CHI, MIM #256450) is a rare genetic disorder caused by genetic mutations in several genes that lead to an excess of insulin secretion in pancreatic β-cells. Pathogenic variations in KATP channels are the most common cause.
Genetic testing is strongly recommended for a rapid and accurate diagnosis of monogenic diabetes or CHI in order to allow the clinician to make a correct diagnosis.
In the past 10 years, the next-generation sequencing (NGS) has revolutionized the field of genomics and created new opportunities for basic research [8,9]. NGS enables the development of faster, more comprehensive and cost-effective genetic methods compared to conventional Sanger sequencing.
In this manuscript, we aim to describe the strategy for the validation of a home-made NGS “dysglycaemia panel” consisting of 44 candidate genes related to glucose metabolism disorders (MODY, WS) and FRG, using Ion AmpliSeq technology combined with Ion-PGM. We also reported the results of the first genetic analyses.
2. Materials and Methods
2.1. Cases Used for Validation
All the procedures adopted for the validation of the home-made NGS “dysglycaemia panel” follow the guidelines reported in ACMG Standards for clinical next-generation sequencing [10].
Sequencing
Thirty-two anonymized DNA samples of patients, previously genotyped by Sanger sequencing, were used to optimize the methodology and perform the panel validation. Different types of mutations such as missense, nonsense, frameshift (Figure 1A) localized in genes responsible for monogenic diabetes, WS, and FRG (Figure 1B) were chosen.
2.2. NGS Ampliseq Protocol
Genomic DNA was extracted from EDTA whole blood using QIAamp DNA Blood Midi kit (Qiagen GmbH, Hilden, Germany) and purified with Amicon Ultra 0.5 mL (Merk Millipore LTD, IRL) according to standard procedures. Eluted DNA was quantified with Nanodrop Spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).
Primers for 44 genes causative of dysglycaemia and its complications were designed using the Thermo Fisher Scientific Ion AmpliSeq Designer platform (version 5.6; www.ampliseq.com (accessed on 30 March 2023)) according to hg19. The list of the genes included in the NGS panel is reported in Table 1.
The primer pairs allowed the amplification of the exons and their flanking regions of all 44 genes. The resulting panel size was 172.857 kb containing 900 amplicons with a coverage of 99% of the targeted regions. All the uncovered parts of the design were sequenced by Sanger sequencing.
A total of 15 ng of DNA from each sample was combined with the Ampliseq reagents and primer pool for the dysglycaemia according to standard protocol. After this step, the amplicon products were partially digested, and IonExpress Adapters and Barcode sequences were ligated to the library fragments. In the following step, the barcoding libraries were cleaned up using a magnetic bead method (Ion Torrent, Thermo Fisher Scientific, Waltham, MA, USA) and then quantified following the Qubit 2.0 fluorimeter (Thermo Fisher Scientific, Waltham, MA, USA) instructions using HS dsDNA kit. The quantified libraries were pooled and diluted once to 100 pM.
The library was amplified by emulsion PCR on Ion sphere particles (ISPs) using the Ion PGM Hi-Q OT2 Kit according to standard protocol (Life Technologies, Carlsbad, CA, USA). Ion 316 chips were used to sequence eight samples simultaneously. Sequencing was performed on an Ion PGM System (Ion Torrent, Thermo Fisher Scientific, Waltham, MA, USA) using the Ion PGM Hi-Q Sequencing kit according to the manufacturer’s instructions. Sequencing data were analyzed with Coverage Analysis and Variant Caller plugins available within the Ion Torrent Suite software TS 5.18 and contextually with Ion Reporter. All the pathogenic or likely pathogenic variants detected by Ion PGM were confirmed using specific couples of primers by direct sequencing of the PCR products.
3. Results
In all the runs, the mean coverage was over 200×, and the mean length of the amplicons was about 200 bp. All data of the variants selected for the evaluation of the “dysglycaemia panel” performance are reported in Table 2, and the results of performance metrics are shown in Table 3. Twenty-nine mutations out of thirty-three were detected by NGS sequencing, while four were missed. Three were frameshift variants ≥ 10bp (c.1279_1358delinsTTACA in GCK exon 10, c.1342_1374del in HNF1a exon 7, c.1261_1280dup19 in SLC5a2 exon 10). One was the duplication of c.872dupC in HNF1a exon 4. Three further variants, classified as variants of uncertain significance (VUS), were detected; all of them were found in the DNA of three unrelated cases in addition to pathogenic variants (Table 4).
4. Discussion
In this study, we report the successful validation of a custom-designed targeted Ampliseq panel for the detection of variants causative of dysglycaemia and its complications. Recently, in the literature, several reports on the application of NGS approach for genetic diagnosis of monogenic diabetes have been published [17,18,19]. All of them are designed to allow the detection of genetic defects causative of monogenic diabetes mellitus (i.e., MODY and neonatal diabetes mellitus) and rare diabetes-associated syndromes (i.e., Wolfram syndrome, Alström syndrome, Wolcott–Rallison syndrome, and thiamine-responsive megaloblastic anemia (TRMA)/Roger’s syndrome) [20]. Based on this information, 44 different genes that are commonly mutated in monogenic diabetes mellitus, congenital hyperinsulinism, Wolfram Syndrome, and familial renal glycosuria were been included in our panel design. We selected anonymized subjects previously genotyped in which thirty-three different variants were present: twenty-nine point mutations or frameshift variants causative of deletion/insertion <10 bp and four frameshift variants caused by deletion/insertion ≥10 bp. The molecular test confirms a good ability to detect point and deletion/insertion mutations of less than 10 bp. In fact, 96.5% of the variants were confirmed. Regarding frameshift variants greater than 10 bp, only one out of four (25%) was detected by the NGS test. Sequencing errors remain a major challenge in the single nucleotide analysis using an NGS platform [21,22].
Ion torrent sequencing system performed by PGM measures the hydrogen ions released during the incorporation of dNTP in the amplification of the DNA target template. The protons release causes a decrease of the pH level in the solution present inside the chip. Ph variation is directly proportional to the number of bases incorporated in the template. When target region is rich of homopolymer repeats, the multiple incorporation of dNTP may lead to a high number of hydrogens released, and a high electronic signal was detected by the sensor. Consequently, variants occurring in this genomic region may be missed [23]
In our study, all the four missed frameshift mutations are not located in the genomic region rich of homopolymers on repeat regions. Therefore, we may suppose that the failure of detection was related to the primer design used for the library amplification, even if the theoretical coverage of HNF1a, GCK, and SLC5a2 genes was predicted as 100% by the Ampliseq primer design tools. As a consequence of this fact, in order to detect these variants, we decided to include in our protocol the Sanger sequencing of GCK exon 10, HNF1a exon 4 and 7, and SLC5a2 exon 11 using specific pairs of primers (available on request).
MODY is defined as an autosomal inherited form of diabetes mellitus caused by mutations in a single gene. In 2013, Lopez et al. described the co-inheritance of HNF1a and GCK mutation in one MODY patient [24]. In the last few years, with the advent of the application of NGS sequencing for genetic diagnosis of monogenic diabetes, further cases of MODY caused by defects in different genes involved in insulin release in response to blood glucose levels have been described [25]. In our validation experiments, three variants that we classified to the best of our knowledge as VUS were detected in two subjects with heterozygous GCK defects and in one with Wolfram syndrome diagnosis (Table 3). Due to the anonymization of the sample used for the panel validation, it is not an aim of this paper to discuss the role of the identified VUS in the clinical phenotype of the three patients. Herein, we only suppose that the difficulty to establish a genotype/phenotype correlation in patients with monogenic diabetes, or to understand the reason that patients with the same defect have frequently different clinical manifestations, may be related to the presence of unidentified variants in other genes that have not been sequenced. This happens principally when genetic diagnosis is performed by Sanger sequencing.
5. Conclusions
In conclusion, our panel based on the Ampliseq approach can be useful for identifying pathogenic variants in multiple genes in a short time. This could help to detect several defects in children and young adults who need to receive a genetic diagnosis necessary for optimal treatment. Sanger sequencing will be included in our analytical protocol to avoid missing frameshift variants due to dysglycaemia.
Author Contributions
Conceptualization, A.S. and C.A.; methodology, A.S., C.A. and F.C.; validation and formal analysis, A.S., C.A. and R.B.; data curation, A.S. and C.A.; writing—original draft preparation, A.S., C.A. and B.T.; writing—review and editing, A.S., C.A., B.T., M.B., N.M., G.d. and M.M.; supervision, N.M., G.d. and M.M.; project administration, M.M.; funding acquisition, M.M. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the “Cinque per mille” and “Ricerca corrente” (Italian Ministry of Health).
Institutional Review Board Statement
This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of IRCCS Istituto Giannina Gaslini.
Informed Consent Statement
Informed consent was obtained from all subjects involved in this study.
Data Availability Statement
Not applicable.
Acknowledgments
We are grateful to the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genova—Department of Excellence—for their support in several steps leading to the approval and publication of this study. This study was also developed within the framework of the DINOGMI, Department of Excellence of MIUR 2018–2022 (legge 232 del 2016).
Conflicts of Interest
The authors declare no conflict of interest.
References
- Hattersley, A.T.; Greeley, S.A.W.; Polak, M.; Rubio-Cabezas, O.; Njølstad, P.R.; Mlynarski, W.; Castano, L.; Carlsson, A.; Raile, K.; Chi, D.V.; et al. ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes 2018, 19, 47–63. [Google Scholar] [CrossRef] [PubMed]
- Kleinberger, J.W.; Pollin, T.I. Undiagnosed MODY: Time for Action. Curr. Diab. Rep. 2015, 12, 110. [Google Scholar] [CrossRef] [PubMed]
- Sanyoura, M.; Philipson, L.H.; Naylor, R. Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options. Curr. Diab. Rep. 2018, 8, 58. [Google Scholar] [CrossRef] [PubMed]
- Urrutia, I.; Martínez, R.; Rica, I.; Martínez de LaPiscina, I.; García-Castaño, A.; Aguayo, A.; Calvo, B.; Castaño, L. Negative autoimmunity in a Spanish pediatric cohort suspected of type 1 diabetes, could it be monogenic diabetes? PLoS ONE 2019, 14, e0220634. [Google Scholar] [CrossRef]
- Gandica, R.G.; Chung, W.K.; Deng, L.; Goland, R.; Gallagher, M.P. Identifying monogenic diabetes in a pediatric cohort with presumed type 1 diabetes. Pediatr. Diabetes 2015, 16, 227–233. [Google Scholar] [CrossRef]
- Wang, J.; Miao, D.; Babu, S.; Yu, J.; Barker, J.; Klingensmith, G.; Rewers, M.; Eisenbarth, G.S.; Yu, L. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J. Clin. Endocrinol. Metab. 2007, 99, 88–92. [Google Scholar] [CrossRef]
- Shepherd, M.; Shields, B.; Hammersley, S.; Hudson, M.; McDonald, T.J.; Colclough, K.; Oram, R.A.; Knight, B.; Hyde, C.; Cox, J.; et al. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care 2016, 39, 1879–1888. [Google Scholar] [CrossRef]
- Yohe, S.; Thyagarajan, B. Review of Clinical Next-Generation Sequencing. Arch. Pathol. Lab. Med. 2017, 141, 1544–1557. [Google Scholar] [CrossRef]
- Fernandez-Marmiesse, A.; Gouveia, S.; Couce, M.L. NGS Technologies as a Turning Point in Rare Disease Research, Diagnosis and treatment. Curr. Med. Chem. 2018, 25, 404–432. [Google Scholar] [CrossRef]
- Rehder, C.; Bean, L.J.H.; Bick, D.; Chao, E.; Chung, W.; Das, S.; O’Daniel, J.; Rehm, H.; Shashi, V.; Vincent, L.M.; et al. Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2021, 8, 1399–1415. [Google Scholar] [CrossRef]
- Li, S.; Yang, Y.; Huang, L.; Kong, M.; Yang, Z. A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a Chinese family, and a review of the relevant literature. Mol. Med. Rep. 2019, 19, 4364–4376. [Google Scholar] [CrossRef] [PubMed]
- Astuti, D.; Sabir, A.; Fulton, P.; Zatyka, M.; Williams, D.; Hardy, C.; Milan, G.; Favaretto, F.; Yu-Wai-Man, P.; Rohayem, J.; et al. Monogenic diabetes syndromes: Locus-specific databases for Alström, Wolfram, and Thiamine-responsivemegaloblastic anemia. Hum. Mutat. 2017, 38, 764–777. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Gong, S.; Han, X.; Zhang, S.; Ren, Q.; Cai, X.; Luo, Y.; Zhou, L.; Zhang, R.; Liu, W.; et al. Genetic variants of ABCC8 and phenotypic features in Chinese early onset diabetes. J. Diabetes 2021, 13, 542–553. [Google Scholar] [CrossRef] [PubMed]
- Qian, X.; Qin, L.; Xing, G.; Cao, X. Phenotype Prediction of Pathogenic Nonsynonymous Single Nucleotide Polymorphisms in WFS1. Sci. Rep. 2015, 5, 14731. [Google Scholar] [CrossRef]
- Colosimo, A.; Guida, V.; Rigoli, L.; Di Bella, C.; De Luca, A.; Briuglia, S.; Stuppia, L.; Salpietro, D.C.; Dallapiccola, B. Molecular Detection of Novel WFS1 Mutations in Patients with Wolfram Syndrome by a DHPLC-Based Assay. Hum. Mutat. 2003, 21, 622–629. [Google Scholar] [CrossRef]
- Pavić, T.; Juszczak, A.; Medvidović, E.P.; Burrows, C.; Šekerija, M.; Bennett, A.J.; Knežević, J.Ć.; Gloyn, A.L.; Lauc, G.; McCarthy, M.I.; et al. Maturity onset diabetes of the young due to HNF1A variants in Croatia. Biochem. Med. 2018, 28, 020703. [Google Scholar] [CrossRef]
- Colclough, K.; Ellard, S.; Hattersley, A.; Patel, K. Syndromic Monogenic Diabetes Genes Should Be Tested in Patients with a Clinical Suspicion of Maturity-Onset Diabetes of the Young. Diabetes 2022, 71, 530–537. [Google Scholar] [CrossRef]
- Philippe, J.; Derhourhi, M.; Durand, E.; Vaillant, E.; Dechaume, A.; Rabearivelo, I.; Dhennin, V.; Vaxillaire, M.; De Graeve, F.; Sand, O.; et al. What Is the Best NGS Enrichment Method for the Molecular Diagnosis of Monogenic Diabetes and Obesity? PLoS ONE 2015, 10, e0143373. [Google Scholar] [CrossRef]
- Campbell, M.R. Review of current status of molecular diagnosis and characterization of monogenic diabetes mellitus: A focus on next-generation sequencing. Expert Rev. Mol. Diagn. 2020, 20, 413–420. [Google Scholar] [CrossRef]
- Zmysłowska, A.; Bodalski, J.; Młynarski, W. The rare syndromic forms of monogenic diabetes in childhood [abstract]. Pediatr. Endrocrinol. Diabetes Metab. 2008, 14, 41–43. [Google Scholar]
- Ma, X.; Shao, Y.; Tian, L.; Flasch, D.A.; Mulder, H.L.; Edmonson, M.N.; Liu, Y.; Chen, X.; Newman, S.; Nakitandwe, J.; et al. Analysis of error profiles in deep next-generation sequencing data. Genome Biol. 2019, 20, 50. [Google Scholar] [CrossRef] [PubMed]
- Pfeiffer, F.; Gröber, C.; Blank, M.; Händler, K.; Beyer, M.; Schultze, J.L.; Mayer, G. Systematic evaluation of error rates and causes in short samples in next-generation sequencing. Sci. Rep. 2018, 8, 10950. [Google Scholar]
- Fujita, S.; Masago, K.; Okuda, C.; Hata, A.; Kaji, R.; Katakami, N.; Hirata, Y. Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton System. Biomed. Rep. 2017, 7, 17–20. [Google Scholar] [CrossRef] [PubMed]
- López-Garrido, M.P.; Herranz-Antolín, S.; Alija-Merillas, M.J.; Giralt, P.; Escribanol, J. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): Implications for genetic testing. Clin. Endocrinol. 2013, 79, 342–347. [Google Scholar] [CrossRef]
- Barbetti, F.; Rapini, N.; Schiaffini, R.; Bizzarri, C.; Cianfarani, S. The application of precision medicine in monogenic diabetes. Expert Rev. Endocrinol. Metab. 2022, 17, 111–129. [Google Scholar] [CrossRef]
Figure 1.
Distribution of types of mutations (A) and genes (B) used to optimize the NGS panel.
Table 1.
“List of genes included in on demand panel” composed by 44 genes causative of dysglycaemia and its complications. AD—autosomal dominant, AR—autosomal recessive, XLR—X-linked recessive, ND—not determined.
Table 1.
“List of genes included in on demand panel” composed by 44 genes causative of dysglycaemia and its complications. AD—autosomal dominant, AR—autosomal recessive, XLR—X-linked recessive, ND—not determined.
| Gene | Location | Phenotype | Phenotype MIM Number | Inheritance |
|---|---|---|---|---|
| ABCC8 | 11p15.1 | MODY, type 12 | 600509 | AD, AR |
| AIRE | 21q22.3 | Autoimmune polyendocrinopathy syndrome, type I, with or without reversible metaphyseal dysplasia | 240300 | AD, AR |
| ALMS1 | 2p13.1 | Alstrom syndrome | 203800 | AR |
| APPL1 | 3p14.3 | MODY, type 14 | 616511 | AD |
| AQP2 | 12q13.12 | Diabetes insipidus, nephrogenic, 2 | 125800 | AD, AR |
| AVPR2 | Xq28 | Diabetes insipidus, nephrogenic, 1 | 304800 | XLR |
| BBS1 | 11q13.2 | Bardet–Biedl syndrome 1 | 209900 | AR, DR |
| BLK | 8p23.1 | MODY, type 11 | 613375 | AD |
| CISD2 | 4q24 | Wolfram syndrome 2 | 604928 | AR |
| DIAPH1 | 5q31.3 | Deafness, autosomal dominant 1, with or without thrombocytopenia/Seizures, cortical blindness, microcephaly syndrome | 124900/616632 | AD/AR |
| GATA6 | 18q11.2 | Pancreatic agenesis and congenital heart defects | 600001 | AD |
| GCK | 7p13 | MODY, type 2 | 125851 | AD |
| GJB2 | 13q12.11 | Deafness, autosomal recessive 1A | 220290 | AR, AD |
| GLIS3 | 9p24.2 | Diabetes mellitus, neonatal, with congenital hypothyroidism | 610199 | AR |
| GLUD1 | 10q23.2 | Hyperinsulinism-hyperammonemia syndrome | 606762 | AD |
| HADH | 4q25 | 3-hydroxyacyl-CoA dehydrogenase deficiency/Hyperinsulinemic hypoglycemia, familial, 4 | 231530/609975 | AR/AR |
| HNF1a | 12q24.31 | MODY, type3 | 600496 | AD |
| HNF1b | 17q12 | MODY, type 5 Renal cysts, and diabetes syndrome | 137920 | AD |
| HNF4a | 20q13.12 | MODY, type 1 | 125850 | AD |
| IL2RA | 10p15.1 | Diabetes mellitus, insulin-dependent, susceptibility to, 10/Immunodeficiency 41 with lymphoproliferation and autoimmunity | 601942/606367 | Nd/AR |
| INS | 11p15.5 | MODY, type 10 | 613370 | AD |
| INSR | 19p13.2 | Hyperinsulinemic hypoglycemia, familial, 5/Leprechaunism/ Rabson–Mendenhall syndrome/Diabetes mellitus, insulin-resistant, with acanthosis nigricans | 609968/246200/262190/ 610549 | AD/AR/AR/Nd |
| KCNJ11 | 11p15.1 | MODY, type 13 | 616329 | AD |
| KFL11 | 2p25.1 | MODY, type 7 | 610508 | AD |
| LRBA | 4q31.3 | Immunodeficiency, common variable, 8, with autoimmunity | 614700 | AR |
| MAGEL2 | 15q11.2 | Schaaf-Yang syndrome | 615547 | AD |
| NeuroD1 | 2q31.3 | MODY, type 6 Maturity-onset diabetes of the young 6 | 606394 | AD |
| OPA1 | 3q29 | Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type)/Behr syndrome/Optic atrophy 1/Optic atrophy plus syndrome/Glaucoma, normal tension, susceptibility | 616896/210000/165500/ 125250/606657 | AR/AR/AD/AD/Nd |
| OPA3 | 19q13.32 | 3-methylglutaconic aciduria, type III/Optic atrophy 3 with cataract | 258501/165300 | AR/ AD |
| PAX4 | 7q32.1 | MODY, type 9 | 612225 | AD |
| PAX6 | 11p13 | Coloboma of optic nerve/Coloboma, ocular/Morning glory disc anomaly/Aniridia/Anterior segment dysgenesis 5, multiple subtypes/Cataract with late-onset corneal dystrophy/Foveal hypoplasia 1/Keratitis/Optic nerve hypoplasia | 120430/120200/120430/ 106210/604229/106210/136520 /148190/165550 | AD/AD/AD/AD/AD/AD/AD/AD/AD |
| PDX1-IPF1 | 13q12.2 | MODY, type IV/Pancreatic agenesis 1/Diabetes mellitus, type II, susceptibility | 606392/260370/125853 | AD/AR/AD |
| POU3F4 | Xq21.1 | Deafness, X-linked 2 | 304400 | XLR |
| RFX6 | 6q22.1 | Mitchell–Riley syndrome | 615710 | AR |
| SEL1L | 14q31.1 | Branchial cleft syndrome involving hypertelorism, preauricular sinus, punctal pits, and deafness | 614187 | AD, AR |
| SH2B1 | 16p11.2 | Severe obesity, insulin resistance, and neurobehavioral abnormalities | 608937 | AD |
| SLC5A2 | 16p11.2 | Renal glucosuria | 233100 | AD, AR |
| SOX9 | 17q24.3 | Acampomelic campomelic dysplasia | 114290 | AD |
| SOX17 | 8q11.23 | Vesicoureteral reflux 3 | 613674 | AD |
| STAT1 | 2q32.2 | Immunodeficiency 31A, mycobacteriosis, autosomal dominant/Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive/Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant | 614892/613796/614162 | AD/AR/AD |
| STAT3 | 17q21.2 | Autoimmune disease, multisystem, infantile-onset, 1/Hyper-IgE recurrent infection syndrome | 615952/147060 | AD/AD |
| STAT5B | 17q21.2 | Growth hormone insensitivity with immune dysregulation 1, autosomal recessive/Growth hormone insensitivity with immune dysregulation 2, autosomal dominant | 245590/618985 | AR/AD |
| TMEM126A | 11q14.1 | Optical trophy 7 | 612989 | AR |
| WFS1 | 4p16.1 | Wolfram Syndrome 1 | 222300 | AR |
Table 2.
Validation data of the “dysglycaemia panel”. ACMG—American College of Medical Genetics and Genomics, Hom—homozygous, P—pathogenic, LP—likely pathogenic, VUS—variants of uncertain significance, B—benign, Nd—not detected. VUS were described in the literature and liked to clinical phenotype.
Table 2.
Validation data of the “dysglycaemia panel”. ACMG—American College of Medical Genetics and Genomics, Hom—homozygous, P—pathogenic, LP—likely pathogenic, VUS—variants of uncertain significance, B—benign, Nd—not detected. VUS were described in the literature and liked to clinical phenotype.
| Sample ID | Gene | Transcript | Mutation Detected by Sanger | Type of Mutation | Detected by NGS | ACMG | Additional Variants |
|---|---|---|---|---|---|---|---|
| Sample 1 | WFS1 | NM_006005.3 | c.2389 G > A; p.Asp797Asn | Missense | Yes | P | |
| Sample 2 | GCK | NM_000162.3 | c.1279_1358delinsTTACA; p.Ser426_Ala454delinsLeuGln | Frameshift ≥ 10 bp | No | LP | PDX1: c.97C > T;p.Pro33Ser |
| Sample 3 | GCK | NM_000162.3 | c.1332_1333_dupGC; p.Ala378dup | Frameshift < 10 bp | Yes | LP | WFS1: c.2194C > T; p.Arg732Cys |
| Sample 4 | HNF1a | NM_000545.8 | c.1027_1029del2; p.Ser343fs74X | Frameshift < 10 bp | Yes | VUS | |
| Sample 5 | SLC5a2 | NM_003041.4 | c.1961A > G; p.Asn654Ser | Missense | Yes | VUS [11] | |
| Sample 7 | HNF1a | NM_000545.8 | c.872dupC;p.Pro291fsinsCys | Frameshift < 10 bp | No | P | |
| Sample 8 | KCNJ11 | NM_000525.3 | c.506 C > T; p.Met169Thr | Missense | Yes | P | |
| Sample 9 | ABCC8 | NM_000352.4 | c.4685delC; p.Pro1563del | Frameshift < 10 bp | Yes | LP | |
| Sample 11 | HNf1b | NM_000458.3 | c.226G > T; p.Gly76Cys (rs144425830) | Missense | Yes | B | |
| Sample 12 | GCK | NM_000162.3 | c.781G > A; p.Gly261Arg | Missense | Yes | P | |
| Sample 13 | GCK | NM_000162.3 | c.1379_*2del22; p.Ala460fs | Frameshift ≥ 10 bp | Yes | LP | |
| Sample 14 | WFS1 | NM_006005.3 | c.1338 C > A; p.Ser446Arg | Missense | Yes | VUS [12] | |
| Sample 16 | WFS1 | NM_006005.3 | c.319 G > C; p.Gly107Arg Hom | Missense | Yes | LP | |
| Sample 17 | ABCC8 | NM_000352.4 | c.916 C > T; p.Arg306Cys | Missense | Yes | VUS [13] | |
| Sample 18 | KCNJ11 | NM_000525.3 | c.601C > T; p.Arg201Cys | Missense | Yes | P | |
| Sample 20 | GCK | NM_000162.3 | c.579 G > T | Synonymous | Yes | LP | |
| Sample 21 | WFS1 | NM_006005.3 | c.1582 T > G; p. Tyr528Asp Hom | Missense | Yes | VUS [14] | |
| Sample 22 | WFS1 | NM_006005.3 | c.2106_2113del8nt; p.V644fs64X Hom | Frameshift < 10 bp | Yes | LP | HNF1a: c.481G > A; p.Ala161Thr |
| Sample 23 | WFS1 | NM_006005.3 | c.1523 A > G; p.Tyr508Cys Hom | Missense | Yes | LP | |
| Sample 25 | HNF1a | NM_000545.8 | c.262delG; p.Glu88fs | Frameshift < 10 bp | Yes | LP | |
| Sample 26 | SLC5a2 | NM_003041.4 | c.1261_1280dup19; p.Glu421_Arg427dup | Frameshift ≥ 10 bp | No | LP | |
| Sample 27 | GCK | NM_000162.3 | c.214G > A; p.Gly72Arg | Missense | c.214G > A; p.Gly72Arg | P | |
| Sample 28 | WFS1 | NM_006005.3 | c.1514G > A; p.Gys505Tyr c.1620_1622delGTG; p.Trp540_Cys541 | Missense Frameshift < 10 bp | c.1514G > A; p.Gys505Tyr c.1620_1622delGTG; p.Trp540_Cys541 | LP/ VUS [15] | |
| Sample 32 | GCK | NM_000162.3 | c.1234T > C; p.Ser412Pro | Missense | c.1234T > C; p.Ser412Pro | P | |
| Sample 33 | HNF1a | NM_000545.8 | c.1342_1374del, p.Val448_Thr458del | Frameshift ≥ 10 bp | Nd | VUS | |
| Sample 34 | SLC5a2 | NM_003041.4 | c.1566C > A; p.Cys522* Hom | Nonsense | c.1566C > A; p.Cys522* Hom | LP | |
| Sample 35 | GCK | NM_000162.3 | c.490delC; p.Leu164Phefs*40 | Frameshift < 10 bp | c.490delC; p.Leu164Phefs*40 | P | |
| Sample 36 | WFS1 | NM_006005.3 | c.1558C > T; p.Gln520* Het | Nonsense | c.1558C > T; p.Gln520* Het | P | |
| Sample 40 | GCK | NM_000162.3 | c.1302C > A; p.Cys434* | Nonsense | c.1302C > A; p.Cys434* | P | |
| Sample 44 | HNF1a | NM_000545.8 | c.1544C > T; p.Thr515Met | Missense | c.1544C > T; p.Thr515Met | VUS [16] | |
| Sample 45 | GCK | NM_000162.3 | c.1174C > T; p.Arg392Cys | Missense | c.1174C > T; p.Arg392Cys | P | |
| Sample 46 | GCK | NM_000162.3 | c.1352T > C; p.Leu451Pro | Missense | c.1544C > T; p.Thr515Met | LP |
Table 3.
Analytical validation of the “dysglycaemia panel”.
| Performance Metric | Value (%) | Approach |
|---|---|---|
| Clinical sensitivity Missense | 100 | 17/17 detected |
| Clinical sensitivity Nonsense | 100 | 3/3 detected |
| Clinical sensitivity Frameshift ≥ 10 bp | 25 | 1/4 detected |
| Clinical sensitivity Frameshift < 10 bp | 87.5 | 7/8 detected |
| Synonymous | 100 | 1/1 detected |
Table 4.
Analysis of the three variants in addition to the variants previously identified by Sanger Sequencing. Het—heterozygous, ACMG—American College of Medical Genetics and Genomics, Mut Taster—MutationTaster, HGMD—Human Gene Mutation Database, VUS—variants of uncertain significance, LP—likely pathogenic, Poss D—possibly damaging, Prob D—probably damaging, D—damaging, Ref—references.
Table 4.
Analysis of the three variants in addition to the variants previously identified by Sanger Sequencing. Het—heterozygous, ACMG—American College of Medical Genetics and Genomics, Mut Taster—MutationTaster, HGMD—Human Gene Mutation Database, VUS—variants of uncertain significance, LP—likely pathogenic, Poss D—possibly damaging, Prob D—probably damaging, D—damaging, Ref—references.
| Patient Code | Gene | Transcript | Variants | Status | ACMG | Clin Var | dbSNP | gnomAD | Polyphen | Sift | Mut Taster | HGMD | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample 2 | PDX1 | NM_000209.4 | c.97 C > T; p.Pro33Ser | Het | VUS | VUS | rs192902098 | 0.00005625 | Poss D | D | D | No | No |
| Sample 3 | WFS1 | NM_006005.3 | c.2194C > T; p.Arg732Cys | Het | LP | VUS | rs71526458 | 0.00006092 | Prob D | D | D | No | No |
| Sample 22 | HNF1a | NM_000545.8 | c.481G > A; p.Ala161Thr | Het | VUS | VUS | rs201095611 | 0.00009549 | Poss D | D | D | CM981897 | Chevre (1998) Diabetologia 41, 1017 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Aloi, C.; Salina, A.; Caroli, F.; Bocciardi, R.; Tappino, B.; Bassi, M.; Minuto, N.; d’Annunzio, G.; Maghnie, M. Next Generation Sequencing (NGS) Target Approach for Undiagnosed Dysglycaemia. Life 2023, 13, 1080. https://doi.org/10.3390/life13051080
AMA Style
Aloi C, Salina A, Caroli F, Bocciardi R, Tappino B, Bassi M, Minuto N, d’Annunzio G, Maghnie M. Next Generation Sequencing (NGS) Target Approach for Undiagnosed Dysglycaemia. Life. 2023; 13(5):1080. https://doi.org/10.3390/life13051080
Chicago/Turabian StyleAloi, Concetta, Alessandro Salina, Francesco Caroli, Renata Bocciardi, Barbara Tappino, Marta Bassi, Nicola Minuto, Giuseppe d’Annunzio, and Mohamad Maghnie. 2023. "Next Generation Sequencing (NGS) Target Approach for Undiagnosed Dysglycaemia" Life 13, no. 5: 1080. https://doi.org/10.3390/life13051080
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
